Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Aegerion Pharmaceuticals logo — Developing advanced therapeutics for cardiovascular and meta...

Aegerion Pharmaceuticals

Developing advanced therapeutics for cardiovascular and metabolic diseases.

Founded 2005 Venture round Total: $63.68M Biotechnology, Health Care +1

General Information

Company Name Aegerion Pharmaceuticals
Founded Year 2005
Founders / Decision Makers
Team member
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Aegerion Pharmaceuticals. To contact Aegerion Pharmaceuticals, visit aegerion.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Aegerion Pharmaceuticals compare?

A PDF of Aegerion Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Aegerion Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Aegerion Pharmaceuticals

Aegerion Pharmaceuticals is a biopharmaceutical company with a focus on developing advanced therapeutics for cardiovascular and metabolic diseases. Founded in 2005, the company is headquartered in Bridgewater, New Jersey. Aegerion has developed lomitapide/AEGR-733, a microsomal triglyceride transfer protein inhibitor small molecule drug designed to reduce serum lipids, including cholesterol and triglycerides. This drug aims to address conditions such as atherosclerosis, dyslipidemia, obesity, and pancreatitis. The company is also dedicated to producing products for the assessment and treatment of hyperlipidemia. Aegerion Pharmaceuticals secured a $1.50M Venture Round investment on 11 October 2010. With its innovative approach to addressing cardiovascular and metabolic diseases, Aegerion Pharmaceuticals is a significant player in the Biotechnology, Health Care, and Health and Wellness industries.

Business keywords: biopharmaceutical company, therapeutics, cardiovascular disease, metabolic disease, lomitapide, microsomal triglyceride transfer protein inhibitor, serum lipids, atherosclerosis, dyslipidemia, obesity, pancreatitis, hyperlipidemia, clinical development, commercialization, pharmaceuticals

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $1.50M -
11 Oct 2010
Venture Round $18.31M -
28 Jun 2010
Convertible Note $3.76M 4
Index Ventures Advent International Alta Partners
Index Ventures, Advent International +2
18 Sep 2008
Series B $17.61M 4
Index Ventures Advent International Alta Partners
Index Ventures, Advent International +2
30 Nov 2007
Series A $22.50M 2
Advent International
Advent International, MVM Life Science Partners
13 Jun 2006

Aegerion Pharmaceuticals Alternatives & Competitors

View All Alternatives
Aegerion Pharmaceuticals vs
BioAge Labs
BioAge Labs United States

We are harnessing the biology of human aging to develop novel targets and therapies for metabolic di...

Series D
99 employees
Biopharma, Biotechnology
Aegerion Pharmaceuticals vs
Gemphire Therapeutics
Gemphire Therapeutics United States

Gemphire is a clinical stage biopharmaceutical company focused on developing and commercializing the...

Private Equity
1 employees
Biotechnology, Health and Wellness
Aegerion Pharmaceuticals vs
Diasome Pharmaceuticals, Inc.
Diasome Pharmaceuticals, Inc.

Diasome Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering hepatocyte cell dru...

Venture round
9 employees
Biotechnology, Health Care
View all alternatives

FAQ About Aegerion Pharmaceuticals

Developing advanced therapeutics for cardiovascular and metabolic diseases.
Aegerion Pharmaceuticals was founded in 2005.
Aegerion Pharmaceuticals operates in Biotechnology, Health Care and Health and Wellness. Its work centres on biopharmaceutical company, therapeutics, cardiovascular disease and metabolic disease.
Aegerion Pharmaceuticals has completed 5 funding rounds, raising a total of $63.68M. The latest funding stage is Venture round.
Top alternatives and competitors to Aegerion Pharmaceuticals include BioAge Labs, Gemphire Therapeutics, Diasome Pharmaceuticals, Inc., Myogen, Amarin Corporation. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Aegerion Pharmaceuticals and BioAge Labs are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Aegerion Pharmaceuticals, https://bouncewatch.com/company/aegerion-pharmaceuticals, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes